



immuno**TX** *summit*

Includes the three focus areas:

Cytokines & Inflammation

Immunotherapeutics & Immunomonitoring

Immunogenicity & Immunotoxicity

JANUARY 30-31, 2018 • SAN DIEGO

Program Partner



Exhibitors





Supporting Sponsors



ABOUT

We invite you to GTCbio's **16th ImmunoTX Summit**, which takes place on **January 30-31, 2018** in **San Diego, CA**. The summit will bring together our usual balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain a fresh perspective on the following topics: Cytokines & Inflammation, Immunotherapeutics & Immunomonitoring and Immunogenicity & Immunotoxicity.

2017 DEMOGRAPHICS



OPPORTUNITIES FOR YOUNG PROFESSIONALS

Breakfast with Mentors from Academia and Industry - The goal of these breakfast meetings is to connect young professionals with experienced mentors from academia and industry who have valuable insights about career options. Young professionals can sign up to spend more time with senior faculty and corporate executives to receive expert advice and guidance.

POSTER PRESENTATION OPPORTUNITIES

If you are interested in participating in the Summit's poster session to showcase your work and research, please submit an abstract [here](#) and select which conference you would like to present in by **December 31, 2017**.

SPONSORSHIP OPPORTUNITIES

Our conferences are designed with our sponsors and exhibitors in mind. We create intimate and highly interactive environments to maximize their reach and make long-lasting contacts. Our sponsors and exhibitors benefit from a few of the following:

- Sponsors/exhibitors have the option to receive the delegate list a week before and a week after the conference.
- The exhibit space for the meeting is shared with any other concurrent conferences, providing sponsors and exhibitors with access to a larger audience. The exhibit space is also where all networking functions take place, including coffee, snack stations, breakfast, and the evening reception.
- Your corporate logo will be placed on the cover page of the conference brochures, the proceedings given to all conference delegates, and on the presentation screen during all breaks to enhance your company's visibility at the event. Your logo will also be placed on the conference website agenda linked to your website.

For sponsorship and exhibit opportunities, please contact:
Amber Kempf, Senior Business Development Manager
amber.kempf@gtcbio.com

SPONSORS

EXHIBIT



Immudex manufactures MHC Dextramers, the leading MHC multimer reagent for the detection of antigen-specific T cells for research and in vitro diagnostics. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.

2015 Bio-IT Best-of-Show-Winner and system of choice for most top-twenty pharma/biotechs, academic/government institutions worldwide, **Studylog** automates and streamlines animal study workflow, mirroring clinical trials processes, making study management easier, faster and more effective for all stakeholders across an enterprise. Studylog securely preserves study conduct information and results for perpetual use.



SQI Diagnostics is a life sciences company that provides clinical grade multiplexed assays and its automated instrumentation to the pharmaceutical research market. SQI develops custom ADA, epitope mapping, multiplexed PK assays, biomarker, and many other assays all in one well making it the leader in the multiplexing of therapeutic proteins, isotypes and subclasses in a single well.

PeproTech creates the building blocks of your life science research by manufacturing high-quality products that advance scientific discovery and human health. Since 1988, PeproTech has grown into a global enterprise manufacturing an extensive line of Recombinant Human, Murine and Rat Cytokines, Animal-Free Recombinant Cytokines, Monoclonal Antibodies, Affinity Purified Polyclonal Antibodies, Affinity Purified Biotinylated Polyclonal Antibodies, ELISA Development Kits, Cell Culture Media Products and GMP Cytokines.



Myriad RBM, Inc. is the world's leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.

Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.



Advanced Targeting Systems provides quality targeting reagents for the specific elimination of cells. The product line includes targeted toxins, antibodies and custom conjugation services (your targeting agent conjugated to your payload). ATS Second Conjugates let researchers create their own targeting tools and are particularly useful to screen antibodies for internalization.

SPONSORS

SUPPORTING



IsoPlexis is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer. The IsoPlexis single cell detection platform isolates single immune cells and analyzes their full functional response, providing predictive biomarkers and assessing the effectiveness of personalized therapies against various cancers.



PROGRAM PARTNER



Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.

Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.



MEDIA PARTNERS



AGENDA AT-A-GLANCE

Day 1 – Tuesday, January 30, 2018

7:30	<i>Registration and Breakfast</i>	
8:30	Opening Keynote Session – Historical Perspective & Current State of the Industry	
10:20	<i>Morning Networking Break</i> <i>Two Parallel Focus Areas</i>	
	Cytokines & Inflammation	Immunotherapeutics & Immunomonitoring
11:05	Metabolic Regulation of Immunity & Inflammation	Novel Targets for Immunotherapy
12:45	<i>Lunch Session – Immunomonitoring & Novel High Throughput Technologies</i>	
2:15	Influence of Microbiome on Immune Responses	Combination Immunotherapy
3:55	<i>Afternoon Networking Break</i>	
4:40	Round Table Discussions	
5:40	<i>Networking Reception and Poster Session</i>	

Day 2 – Wednesday, January 31, 2018

7:15	<i>Breakfast with Mentors from Academia and Industry - RSVP only</i>	
7:30	<i>Continental Breakfast</i>	
	<i>Two Parallel Focus Areas</i>	
	Cytokines & Inflammation	Immunogenicity & Immunotoxicity
8:30	Targeting Cytokines for Therapeutic Interventions	Molecular Mechanisms & Strategic Modulation of Immunogenicity
10:10	<i>Morning Networking Break</i>	
10:40	Innate Immunity in Respiratory Diseases	Immunogenicity Assessment of Novel Drug Candidates & Biosimilars
12:20	<i>Lunch provided by GTCbio</i>	
1:35	Award Ceremony & Closing Keynote Session – Predictions for the Future	
2:35	Keynote Panel Discussion	
3:20	<i>Summit Concludes</i>	

ImmunoTX Summit

KEYNOTE SPEAKERS



Opening Keynote Session: Historical Perspective & Current State of the Industry

Erika Brown
PALTOWN Development Foundation



Immune Control of Liver Tumorigenesis: From Basic Mechanisms to Cancer Therapy

Michael Karin
University of California, San Diego



Opening Keynote Session: Historical Perspective & Current State of the Industry

Scott Durum
NIH - National Cancer Center - Center for Cancer Research



Closing Keynote Session: Predictions for the Future

Jennifer Towne
Janssen



PD-1 Cancer Immunotherapy

Gordon Freeman
Dana Farber Cancer Institute, Harvard University



Closing Keynote Session: Predictions for the Future

Andrew Vandergrift
Ignyta


Cytokines & Inflammation

DISTINGUISHED SPEAKERS



Targeting IL-17 in Neuroinflammation: More to it Than Meets the Eye

Rachel Caspi
NEI, NIH



Middle East Respiratory Syndrome: Insights into Role of Type 1 Interferon

Kingston HG Mills
Trinity Biomedical Sciences Institute

Session: Influence of Microbiome on Immune Responses



Manoj Dadlani
CosmosID



Metabolism of Lupus T cells

Laurence Morel
University of Florida



John Eid
Whole Biome



Regulation of Allergic Responses to Food by Commensal Bacteria

Cathryn Nagler
The University of Chicago

Cytokines & Inflammation

DISTINGUISHED SPEAKERS



Emerging Therapies for Atopic Dermatitis

Michael Howell
Incyte Corporation



Session: Influence of Microbiome on Immune Responses

Take Ogawa
Second Genome



Session: Metabolic Regulation of Immunity & Inflammation

Alison Humbles
MedImmune



Middle East Respiratory Syndrome: Insights into Role of Type 1 Interferon

Stanley Perlman
University of Iowa



Session: Innate Immunity in Respiratory Diseases

Ignacio Juncadella
Boehringer Ingelheim



Targeting Cytokines for Therapeutic Interventions

Thomas Schall
ChemoCentryx



Session: Targeting Cytokines for Therapeutic Interventions

Dermot McGovern
Cedars-Sinai Medical Center, UCLA School of Medicine

Immunotherapeutics & Immunomonitoring DISTINGUISHED SPEAKERS



T-SIGn Oncolytic Viruses: Systemic Delivery for Localized Production of Immunotherapeutic Combinations within Tumors

Brian Champion
PsiOxus Therapeutics



Combinatorial Approaches for Cancer Immunotherapy Using Anti-CD40 Antibody

Alexander Rakhmilevich
University of Wisconsin-Madison



IGN002: A Focused ImmunoTherapeutic (FIT) for NHL

Michael Gresser
Immungene



Next Generation Combination Strategies to Enhance CAR Products for Multiple Myeloma

Blythe Sather
Juno Therapeutics

Session: Novel Targets for Immunotherapy



Karin Jooss
Gritstone



Combined Inhibition of IDO1 and PD-1 as an Effective Therapeutic Strategy in Cancer

Peggy Scherle
Incyte



Antitumor Effects of Combination Immunotherapy

Joost Oppenheim
NIH NCI



Multivalent Adoptive Cell Therapy Using Novel XPRESIDENT® Derived Targets

Steffen Walter
Immatics

Immunogenicity & Immunotoxicity DISTINGUISHED SPEAKERS



Session: Molecular Mechanisms & Strategic Modulation of Immunogenicity

Annie De Groot
Epivax



Challenges and Solutions in Immunogenicity Assessment of Novel Drug Candidates

Meina Liang
MedImmune



Mitigation of Immunogenicity with Tolerogenic Nanoparticles

Kei Kishimoto
Selecta Biosciences



Engineered Specific Regulatory T cells Block Adverse Immune Responses

David W. Scott
Uniformed Services University of Health Sciences

Immunogenicity & Immunotoxicity

DISTINGUISHED SPEAKERS



Expanding the Utility of a Functional Reporter Gene Assay to Clinical Monitoring of TNF Antagonist Biosimilars

Eszter Lazar-Molnar
ARUP Laboratories



Mitigation of Immunogenicity with Tolerogenic Nanoparticles

Albert J Wong
Stanford University Medical Center



Hong-Gee Lee
PBL Assay Science